These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 16369867)
1. Target HCV NS3 CD4+ Th1 epitope to major histocompatibility complex class II pathway. Gao M; Wang HP; Wang YN; Zhou Y; Wang QL Biotechnol Lett; 2006 Jan; 28(1):3-8. PubMed ID: 16369867 [TBL] [Abstract][Full Text] [Related]
2. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo. Gao M; Wang HP; Wang YN; Zhou Y; Wang QL Vaccine; 2006 Jun; 24(26):5491-7. PubMed ID: 16725235 [TBL] [Abstract][Full Text] [Related]
3. [Construction of hepatitis C virus-NS3 Th1 plasmid vaccine based on MHC class II-associated invariant chain peptide substitution]. Gao M; Wang HP; Lu Y; Zhou Y; Wang YN; Zhan LS; Wang QL Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):309-10. PubMed ID: 20460057 [No Abstract] [Full Text] [Related]
4. DNA vaccine using invariant chain gene for delivery of CD4+ T cell epitope peptide derived from Japanese cedar pollen allergen inhibits allergen-specific IgE response. Toda M; Kasai M; Hosokawa H; Nakano N; Taniguchi Y; Inouye S; Kaminogawa S; Takemori T; Sakaguchi M Eur J Immunol; 2002 Jun; 32(6):1631-9. PubMed ID: 12115646 [TBL] [Abstract][Full Text] [Related]
6. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768 [TBL] [Abstract][Full Text] [Related]
7. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104 [TBL] [Abstract][Full Text] [Related]
8. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination. Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415 [TBL] [Abstract][Full Text] [Related]
9. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Hervas-Stubbs S; Majlessi L; Simsova M; Morova J; Rojas MJ; Nouzé C; Brodin P; Sebo P; Leclerc C Infect Immun; 2006 Jun; 74(6):3396-407. PubMed ID: 16714570 [TBL] [Abstract][Full Text] [Related]
10. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
11. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057 [TBL] [Abstract][Full Text] [Related]
12. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers. Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of chicken major histocompatibility complex class II oligomers using a baculovirus expression system. Niemiec PK; Read LR; Sharif S Protein Expr Purif; 2006 Apr; 46(2):390-400. PubMed ID: 16236525 [TBL] [Abstract][Full Text] [Related]
14. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486 [TBL] [Abstract][Full Text] [Related]
15. Establishment of an expression cloning system for CD4+ T cell epitopes. Fujii S; Uemura Y; Iwai LK; Ando M; Senju S; Nishimura Y Biochem Biophys Res Commun; 2001 Jun; 284(5):1140-7. PubMed ID: 11414702 [TBL] [Abstract][Full Text] [Related]
17. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Dobaño C; Rogers WO; Gowda K; Doolan DL Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849 [TBL] [Abstract][Full Text] [Related]
18. Interactions between helper T-cell epitopes of hepatitis C virus. Zhu F; Yang M; Eckels DD Vaccine; 2005 May; 23(27):3572-80. PubMed ID: 15855016 [TBL] [Abstract][Full Text] [Related]
19. Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions. Cecconi V; Moro M; Del Mare S; Dellabona P; Casorati G Cytometry A; 2008 Nov; 73(11):1010-8. PubMed ID: 18612991 [TBL] [Abstract][Full Text] [Related]
20. Identification of a CD4 T-cell epitope in tumor rejection antigen RLakt on BALB/c radiation-leukemia RL male 1. Kaya S; Uenaka A; Sato S; Ono T; Aji T; Nakayama E Cancer Sci; 2008 Jul; 99(7):1441-7. PubMed ID: 18452555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]